Users Share Regrets Over Unregulated Peptides Amid Freedom Debate

WHO:

CNN - Dylan Meetze, a user of BPC-157, reported negative side effects.

CNN - Andrew Huberman, a Stanford neuroscientist and influencer with over 16 million followers, promotes peptides.

CNN - Craig Koniver, a doctor who sells peptides, referred to BPC-157 as “super safe.”

CNN - Robert F. Kennedy Jr., health secretary, advocates for easing restrictions on peptides.

CNN - Reshma Ramachandran, a regulatory science researcher at Yale School of Medicine, commented on the medical freedom debate.

CNN - Eric Topol, executive vice president of Scripps Research, expressed concerns about the lack of clinical trials.

CNN - Peter Lurie, a former FDA official, criticized the push for unapproved peptides.

CNN - Dominik E., a software engineer, shared his experience with BPC-157 and TB-4.

CNN - Lois S., a Michigan elementary school worker, described her experience with BPC-157 and retatrutide.

WHAT:

CNN - Dylan Meetze experienced fatigue, anxiety, and muscle twitches after using BPC-157.

CNN - More than 1,000 people reported using BPC-157 to their doctors since 2020.

CNN - The FDA panel voted to ease restrictions on six experimental peptides, including BPC-157, TB-500, and MOTS-c.

CNN - The FDA has not approved BPC-157 or many other peptides due to lack of clinical trials.

CNN - An FDA database contains reports of adverse events related to experimental peptides.

CNN - Two women were hospitalized after being injected with experimental peptides at an antiaging conference.

WHERE:

CNN - BPC-157 was purchased online from a vendor named Researchem, which is associated with an address in Hillsboro, Oregon.

CNN - The FDA meeting where the vote took place occurred in July.

WHEN:

CNN - The FDA meeting where the panel voted to ease restrictions occurred in July.

CNN - A podcast episode featuring Andrew Huberman discussing BPC-157 had 1.2 million views in 2024.

WHY:

CNN - Robert F. Kennedy Jr. aims to end the “aggressive suppression” of peptides and promote their accessibility.

CNN - Proponents argue that shoddy manufacturing, not the peptides themselves, causes harm.

HOW:

CNN - BPC-157 is marketed online as a remedy for various health issues despite being labeled for laboratory research only.

CNN - The FDA's 503A list would allow specialized pharmacies to make unapproved peptides for human use if the restrictions are eased.

(UPDATED October 14, 2026 03:03 UTC)

In a recent report, Dylan Meetze shared his negative experiences with BPC-157, including fatigue and anxiety, after using the peptide, which has not been approved by the FDA due to a lack of clinical trials. Meanwhile, an FDA panel voted to ease restrictions on several experimental peptides, including BPC-157, TB-500, and MOTS-c, despite concerns from experts like Eric Topol and Peter Lurie about the potential risks associated with unapproved substances. Advocates, including health secretary Robert F. Kennedy Jr., are pushing for greater accessibility to these peptides, arguing that issues stem from poor manufacturing rather than the peptides themselves.